|
1
|
Bauer KR, Brown M, Cress RD, Parise CA and
Caggiano V: Descriptive analysis of estrogen receptor
(ER)-negative, progesterone receptor (PR)-negative, and
HER2-negative invasive breast cancer, the so-called triple-negative
phenotype: A population-based study from the California cancer
Registry. Cancer. 109:1721–1728. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Arpino G, Weiss H, Lee AV, Schiff R, De
Placido S, Osborne CK and Elledge RM: Estrogen receptor-positive,
progesterone receptor-negative breast cancer: Association with
growth factor receptor expression and tamoxifen resistance. J Natl
Cancer Inst. 97:1254–1261. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shi X, Lin XY, Huang Y, Zhang ZF, Wang RX
and Zeng WC: Expressions of ER, PR, Her-2 in breast cancer. Zhong
Liu Yan Jiu Yu Lin Chuang. 21:461–462,465. 2009.[(In Chinese)].
|
|
4
|
Kuiper GG, Enmark E, Pelto-Huikko M,
Nilsson S and Gustafsson JA: Cloning of a novel receptor expressed
in rat prostate and ovary. Proc Natl Acad Sci USA. 93:5925–5930.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chang HG, Kim SJ, Chung KW, Noh DY, Kwon
Y, Lee ES and Kang HS: Tamoxifen-resistant breast cancers show less
frequent methylation of the estrogen receptor β but not the
estrogen receptor α gene. J Mol Med (Berl). 83:132–139. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cappelletti V, Celio L, Bajetta E, Allevi
A, Longarini R, Miodini P, Villa R, et al: Prospective evaluation
of estrogen receptor-β in predicting response to neoadjuvant
antiestrogen therapy in elderly breast cancer patients. Endocr
Relat Cancer. 11:761–770. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Esslimani-Sahla M, Kramar A,
Simony-Lafontaine J, Warner M, Gustafsson JA and Rochefort H:
Increased estrogen receptor betacx expression during mammary
carcinogenesis. Clin Cancer Res. 11:3170–3174. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Thomas C and Gustafsson JÅ: The different
roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer.
11:597–608. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yager JD and Davidson NE: Estrogen
carcinogenesis in breast cancer. N Engl J Med. 354:270–282. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Dotzlaw H, Leygue E, Watson PH and Murphy
LC: Expression of estrogen receptor-β in human breast tumors. J
Clin Endocrinol Metab. 82:2371–2374. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Young SR, Pilarski RT, Donenberg T,
Shapiro C, Hammond LS, Miller J, Brooks KA, Cohen S, Tenenholz B,
Desai D, et al: The prevalence of BRCA1 mutations among young women
with triple-negative breast cancer. BMC Cancer. 9:862009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dent R, Hanna WM, Trudeau M, Rawlinson E,
Sun P and Narod SA: Pattern of metastatic spread in triple-negative
breast cancer. Breast Cancer Res Treat. 115:423–428. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sengupta S, Sharma CG and Jordan VC:
Estrogen regulation of X-box binding protein-1 and its role in
estrogen induced growth of breast and endometrial cancer cells.
Horm Mol Biol Clin Investig. 2:235–243. 2010.PubMed/NCBI
|
|
14
|
Speirs V, Adams IP, Walton DS and Atkin
SL: Identification of wild-type and exon 5 deletion variants of
estrogen receptor beta in normal human mammary gland. J Clin
Endocrinol Metab. 85:1601–1605. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Reis-Filho JS and Tutt AN: Triple negative
tumours: A critical review. Histopathology. 52:108–118. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vinayagam R, Sibson DR, Holcombe C, Aachi
V and Davies MP: Association of oestrogen receptor beta 2 (ER beta
2/ER beta cx) with outcome of adjuvant endocrine treatment for
primary breast cancer - a retrospective study. BMC Cancer.
7:1312007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Järvinen TA, Pelto-Huikko M, Holli K and
Isola J: Estrogen receptor β is coexpressed with ERα and PR and
associated with nodal status, grade, and proliferation rate in
breast cancer. Am J Pathol. 156:29–35. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hou YF, Yuan ST, Li HC, Wu J, Lu JS, Liu
G, Lu LJ, Shen ZZ, Ding J and Shao ZM: ERβ exerts multiple
stimulative effects on human breast carcinoma cells. Oncogene.
23:5799–5806. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Knowlden JM, Gee JM, Robertson JF, Ellis
IO and Nicholson RI: A possible divergent role for the oestrogen
receptor α and β subtypes in clinical breast cancer. Int J Cancer.
89:209–212. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jensen EV, Cheng G, Palmieri C, Saji S,
Mäkelä S, Van Noorden S, Wahlström T, Warner M, Coombes RC and
Gustafsson JA: Estrogen receptors and proliferation markers in
primary and recurrent breast cancer. Proc Natl Acad Sci USA.
98:15197–15202. 2001. View Article : Google Scholar : PubMed/NCBI
|
